ViVac has achieved a major scientific milestone with confirmed in vivo RNA expression  and tumor-targeted delivery  using its proprietary synthetic RNA–Lipid Nanoparticle (LNP) platform. The data validate the company’s vision of combining viral potency with RNA-level safety to create a new generation of localized cancer immunotherapies. The results demonstrate that ViVac’s engineered RNA replicons can safely express within tumor cells while remaining self-limiting — a breakth

ViVac announced the appointment of Keren Leshem as Chief Executive Officer, marking a significant milestone in the company’s evolution from research-driven startup to emerging leader in RNA-based cancer immunotherapy. Leshem, a World Economic Forum Technology Pioneer CEO , has been recognized by Forbes and Entrepreneur as one of the most influential voices in biotechnology. She brings over two decades of experience building and scaling clinical-stage life science companies